|
Treatment
| |
Day of study
|
|---|
| |
8
|
15
|
22
|
29
|
36
|
|---|
|
Placebo
|
Range
|
17–27
|
20–28
|
15–26
|
19–26
|
19–26
|
|
Arithmetic Mean (AM)
|
21.00
|
24.13
|
23.75
|
22.25
|
22.88
|
|
Geometric Mean (GM)a
|
20.70
|
23.95
|
23.44
|
22.13
|
22.78
|
|
Sarolaner
|
Range
|
0–6
|
0–1
|
0–3
|
0–3
|
0–3
|
|
Arithmetic mean (AM)
|
1.75
|
0.25
|
0.38
|
1.25
|
0.75
|
|
AM Efficacy (%)
|
91.67
|
98.96
|
98.42
|
94.38
|
96.72
|
|
Geometric mean (GM)a
|
1.26
|
0.19
|
0.19
|
0.96
|
0.49
|
|
GM Efficacy (%)
|
93.93
|
99.21
|
99.19
|
95.67
|
97.86
|
|
Test statistic vs placebo
|
t
(34) = 12.26
|
t
(34) = 16.48
|
t
(34) = 16.37
|
t
(34) = 13.37
|
t
(34) = 15.01
|
|
P-value vs placebo
|
< 0.0001
|
< 0.0001
|
< 0.0001
|
< 0.0001
|
< 0.0001
|
|
Afoxolaner
|
Range
|
0–5
|
0–1
|
0–6
|
0–5
|
0–8
|
|
Arithmetic mean (AM)
|
2.00
|
0.25
|
2.75
|
1.75
|
2.75
|
|
AM Efficacy (%)
|
90.48
|
98.96
|
88.42
|
92.13
|
87.98
|
|
Geometric mean (GM)a
|
1.41
|
0.19
|
1.78
|
1.14
|
1.85
|
|
GM Efficacy (%)
|
93.17
|
99.21
|
92.42
|
94.87
|
91.89
|
|
Test statistic vs placebo
|
t
(46) = 8.70
|
t
(46) = 12.06
|
t
(46) = 8.62
|
t
(46) = 9.44
|
t
(46) = 8.41
|
|
P-value vs placebo
|
< 0.0001
|
< 0.0001
|
< 0.0001
|
< 0.0001
|
< 0.0001
|
|
Test statistic vs sarolaner
|
t
(70) = 0.22
|
t
(70) = 0.00
|
t
(70) = 2.80
|
t
(70) = 0.29
|
t
(70) = 2.14
|
|
P-value vs sarolaner
|
0.8247
|
1.0000
|
0.0066
|
0.7757
|
0.0356
|
-
a
P-values are based on comparison of geometric means
